A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Registrational; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 06 Mar 2018 Planned End Date changed from 11 Dec 2019 to 20 Sep 2021.
- 06 Mar 2018 Planned primary completion date changed from 11 Jul 2018 to 30 Jul 2018.
- 20 Feb 2018 According to an Ultragenyx media release, data from this study is expected in the second half of 2018